Wird geladen...
Phase 1 study of an AKT-inhibitor (MK-2206) combined with lapatinib in adult solid tumors followed by dose-expansion in advanced HER2+ breast cancer
PURPOSE: Preclinical data supports combining AKT-inhibitors with human epidermal growth factor receptor-2 (HER2) targeted therapies to overcome resistance to treatment. This Phase 1 study combined the investigational AKT inhibitor, MK-2206, with lapatinib to determine the maximum tolerated dose (MTD...
Gespeichert in:
| Veröffentlicht in: | Clin Cancer Res |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4891227/ https://ncbi.nlm.nih.gov/pubmed/27026198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2365 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|